Letolizumab
In this article we are going to talk about Letolizumab, a topic that has been present throughout history and that continues to be relevant in today's society. Letolizumab has aroused great interest and debate, both in academia and in public opinion, due to its impact on different aspects of daily life. Over time, Letolizumab has been the subject of studies, research and reflections that have contributed to expanding our understanding of this topic. In this sense, we will address different perspectives and approaches to better understand the importance and meaning of Letolizumab today.
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized (from mouse) |
| Target | tumor necrosis factor-related activation protein |
| Clinical data | |
| Other names | BMS-986004 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1734H2688N466O538S10 |
| Molar mass | 38991.90 g·mol−1 |
Letolizumab (INN; development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
This drug was developed by Bristol-Myers Squibb.
References
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
- ^ Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK (2019). "Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India". Psoriasis: Targets and Therapy. 9: 19–27. doi:10.2147/PTT.S154073. PMC 6501705. PMID 31119094.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |